Mayne Pharma announces new CEO appointment


The Chairman of Mayne Group Limited (Mayne), Mr Peter Willcox, announced the Board will be appointing Dr Thierry Soursac as Chief Executive Officer and Managing Director for Mayne Pharma upon Mayne's shareholders giving approval to proceed with the demerger and the demerger becoming effective.

Dr Soursac studied medicine at the School of Medicine of Angers and subsequently specialised in oncology in France. After completing an MD in 1981, he became assistant professor in oncology, operated a clinical oncology practice and established and led the pharmacokinetics research department at the Paul Papin Center for five years. During this time Dr Soursac also completed a PhD in clinical pharmacology and pharmacokinetics at Pitie-Salpetriere University in Paris.

After completing an MBA at INSEAD in 1986, Dr Soursac was appointed a hospital pharmaceutical sales representative for Rhone-Poulenc. He was promoted to Head of Marketing of the French affiliate in 1988 and in 1990, following the merger with Rorer to form RPR, he was promoted to Corporate Vice President responsible for Marketing and Corporate Strategy globally for the merged company.

In 1994 Dr Soursac was promoted to Senior Vice President and established a gene therapy capability for RPR by forming Gencell, based in Santa Clara, California. In 1997, he became President of Worldwide Research for RPR and in 1998, he was promoted to Executive Vice President leading the Corporate Marketing, Business and Technology Development and Corporate Development activities at RPR. In January 1999, he was appointed President of Worldwide Pharmaceutical Operations responsible for all proprietary and generic business worldwide, all affiliates around the world, as well as global marketing and medical affairs.

In January 2000, RPR merged with Hoechst Marion Roussel to form Aventis and Dr Soursac was appointed Executive Vice President and Head of Commercial Operations worldwide for Aventis Pharma and a member of the Executive Committee. In 2002, he became a member of the Management Board of Aventis SA. Dr Soursac decided to leave Sanofi-Aventis at the end of 2004 following its acquisition by Sanofi.

Dr Soursac's appointment as CEO of Mayne Pharma is subject to Mayne's shareholders approving the proposed demerger and he will take up his appointment on the effective date of the demerger. In the meanwhile, under the terms of the arrangement, Dr Soursac will begin consulting to Mayne on 1 October 2005.

Other news from the department people

Most read news

More news from our other portals

Is artificial intelligence revolutionising chemistry?